Acumen Pharmaceuticals Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Acumen Pharmaceuticals Inc's ROI in the second quarter of 2026?
Acumen Pharmaceuticals Inc recorded a cumulative net loss of $-105 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -96.59%.

Within the Healthcare sector 619 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3410 to 4008.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	-46.51 %	-45.7 %	-42.56 %	-37.28 %	-28.87 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	89	113	103	130	158
Return On Investment (TTM)	-96.59 %	-89.84 %	-82.48 %	-76.6 %	-67.21 %
ABOS's Overall Ranking	# 4008	# 3410	# 3393	# 3688	# 3173
Seq. Investment Change TTM	-13.74 %	-14.3 %	-15.5 %	-14.37 %	-12.43 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-105	-113	-121	-133	-137

ABOS Company Profile >> Back to ABOS Roi Comparisons >> See Annual ABOS Return On Investment

Return On Investment ABOS's Ranking
Within:	No.
Industry	# 99
Sector	# 620
Overall	# 4008

Return On Investment Statistics
High	Average	Low
-14.25 %	-59.76 %	-350.44 %
(Jun 30 2022)		(Jun 30 2021)

Financial Statements
Acumen Pharmaceuticals Inc's II. Quarter Investments	$ 89 Millions	ABOS's Balance sheet
Acumen Pharmaceuticals Inc's II. Quarter Income	$ -33 Millions	Quarterly ABOS's Income Statement
ABOS's Income by Division		See ABOS's Income by Division

ABOS Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	93	211	297	189	229
Y / Y Investment Growth	-56.09 %	-28.86 %	57.41 %	-17.65 %	-
Net Income in Millions	-121	-102	-52	-43	-101
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-130.71 %	-48.41 %	-17.62 %	-22.7 %	-43.89 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ABOS's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ABOS's Competitors
Subscribers only: Roi for Acumen Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for ABOS's Customers

Other Ratios
ABOS's Roa	ABOS's Inventory Turnover Ratio	ABOS's Growth Rates	ABOS's Dividend Statistics
	ABOS's Profitability Ratios	ABOS's Asset Turnover Ratio	ABOS's Dividend Growth
ABOS's Roe	ABOS's Valuation Ratios	ABOS's Financial Strength Ratios	ABOS's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-26T07:40:22+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.